Master in 바이오의약융합전공

The Biopharmaceutical Convergence Major at Sungkyunkwan University (SKKU), based in Jongno-gu, South Korea, is a master's degree focused on the science behind developing biologically derived medicines, including antibodies, vaccines, and other protein-based therapeutics. Coursework typically covers molecular biology, protein engineering, pharmacology, and the manufacturing and quality control processes used to produce biopharmaceuticals at scale. Students study how biological drugs differ from traditional chemical medicines, how they are designed and tested for safety and efficacy, and how regulatory pathways govern their approval for clinical use. Given the convergence framing of the major, coursework often draws on biology, chemistry, and pharmaceutical science together, reflecting how biopharmaceutical development rarely fits neatly into one traditional discipline. Graduates commonly move into roles at pharmaceutical and biotechnology companies, contract manufacturing organizations, and regulatory agencies, with positions such as research scientist, bioprocess engineer, or regulatory affairs specialist. Korea's biopharmaceutical manufacturing sector, which has grown considerably, is a common destination for graduates of programs like this one. Training combines coursework with laboratory-based research, and students are generally expected to complete a thesis addressing a specific question in drug development or biologics manufacturing. The program runs two years, with new students admitted in March and September of every year, and instruction is delivered in English, supporting a mixed cohort of domestic and international students. Applicants typically hold undergraduate degrees in biology, biochemistry, chemical engineering, or pharmacy, and the program builds toward specialized expertise in the fast-growing field of biologic medicine.